1. Kyoto University Research Information Repository
  2. 060　医学研究科・医学部・医学部附属病院
  3. 泌尿器科紀要
  4. Vol.34 No.10
このアイテムのアクセス数: 252

    このアイテムの引用には次の識別子を使用してください: http://hdl.handle.net/2433/119751
このアイテムのファイル:
ファイル 記述 サイズフォーマット 
34_1693.pdf1.81 MBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド値言語
dc.contributor.author原, 眞ja
dc.contributor.author寺島, 保典ja
dc.contributor.author金森, 幸男ja
dc.contributor.author千賀, 康弘ja
dc.contributor.author近藤, 幸壽ja
dc.contributor.author大原, 正雄ja
dc.contributor.author坪井, 成美ja
dc.contributor.author西村, 泰司ja
dc.contributor.author秋元, 成太ja
dc.contributor.alternativeHARA, Makotoen
dc.contributor.alternativeTERASHIMA, Yasunorien
dc.contributor.alternativeKANAMORI, Sachioen
dc.contributor.alternativeSENGA, Yasuhiroen
dc.contributor.alternativeKONDOH, Yukihiroen
dc.contributor.alternativeOHHARA, Masaoen
dc.contributor.alternativeTSUBOI, Narumien
dc.contributor.alternativeNISHIMURA, Taijien
dc.contributor.alternativeAKIMOTO, Masaoen
dc.date.accessioned2010-06-02T02:57:50Z-
dc.date.available2010-06-02T02:57:50Z-
dc.date.issued1988-10-
dc.identifier.issn0018-1994-
dc.identifier.urihttp://hdl.handle.net/2433/119751-
dc.description.abstract進行性尿路腫瘍8例にIL-2を投与し, その抗腫瘍効果, 副作用などにつき検討した.1) IL-2を28日以上投与しえた5症例のうち, 1例に膀胱癌の肝転移巣の50%以上の縮小を認めた.さらに他の1例にperformance statusの著明な改善を認めた.2) IL-2投与中に, 患者の末梢血NK, LAK活性の上昇傾向を認めた.3)主な副作用として, 発熱, 精神障害, 低血圧, 好酸球増多などを認めた.重篤な副作用として, 心不全, 腎機能障害も認められたja
dc.description.abstractEight patients with advanced cancer of the urinary tract were treated with recombinant interleukin-2(IL-2) at our department between December, 1985 and September, 1987. Patients were given 5 x 10(5)-4 x 10(6) units of IL-2 by intravenous drip infusion daily. One of five patients who received IL-2 for over 28 days showed 62% regression in size of hepatic metastasis of bladder cancer on computed tomography and another showed marked improvement of Performance Status. The upward tendency of natural killer and lymphokine-activated killer activity of peripheral blood was observed during treatment. Fever, mental disturbance, hypotension and eosinophilia and others were recognized during administration of IL-2, and cardiac failure and disturbance of renal function were also recognized as severe side effect.en
dc.format.mimetypeapplication/pdf-
dc.language.isojpn-
dc.publisher泌尿器科紀要刊行会ja
dc.subjectInterieukin-2 (IL-2). Bladder tumoren
dc.subjectRenal tumoren
dc.subject.ndc494.9-
dc.title進行性尿路腫瘍に対するInterleukin2(IL-2)による治療ja
dc.title.alternativeTreatment of advanced cancer of the urinary tract with interleukin-2 (IL-2)en
dc.typedepartmental bulletin paper-
dc.type.niitypeDepartmental Bulletin Paper-
dc.identifier.ncidAN00208315-
dc.identifier.jtitle泌尿器科紀要ja
dc.identifier.volume34-
dc.identifier.issue10-
dc.identifier.spage1693-
dc.identifier.epage1696-
dc.textversionpublisher-
dc.sortkey01-
dc.address日本医科大学泌尿器科学教室ja
dc.address日本医科大学泌尿器科学教室ja
dc.address日本医科大学泌尿器科学教室ja
dc.address日本医科大学泌尿器科学教室ja
dc.address日本医科大学泌尿器科学教室ja
dc.address日本医科大学泌尿器科学教室ja
dc.address日本医科大学泌尿器科学教室ja
dc.address日本医科大学泌尿器科学教室ja
dc.address日本医科大学泌尿器科学教室ja
dc.address.alternativethe Department of Urology Nippon Medical Schoolen
dc.address.alternativethe Department of Urology Nippon Medical Schoolen
dc.address.alternativethe Department of Urology Nippon Medical Schoolen
dc.address.alternativethe Department of Urology Nippon Medical Schoolen
dc.address.alternativethe Department of Urology Nippon Medical Schoolen
dc.address.alternativethe Department of Urology Nippon Medical Schoolen
dc.address.alternativethe Department of Urology Nippon Medical Schoolen
dc.address.alternativethe Department of Urology Nippon Medical Schoolen
dc.identifier.pmid3266712-
dcterms.accessRightsopen access-
dc.identifier.pissn0018-1994-
dc.identifier.jtitle-alternativeActa urologica Japonicala
dc.identifier.jtitle-alternativeHinyokika Kiyoen
出現コレクション:Vol.34 No.10

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。